Sanofi is following in the footsteps of a number of its peers in pharma with a plan to spin off its consumer health business into a separate company and focus its efforts on its prescription drugs business.

赛诺菲正在跟随制药公司一些同行的脚步，计划将其消费者健康业务分为一家独立的公司，并将其工作重点放在处方药业务上。

In its third-quarter results update, Sanofi said the consumer health unit – which owns brands like allergy therapies Allegra and Xyzal, irritable bowel syndrome product Buscopan, painkiller Doliprane and Pharmaton dietary supplement – will separate in the fourth quarter of 2024 “at the earliest.”

赛诺菲表示，在其第三季度的结果更新中，消费者健康部门-拥有过敏疗法Allegra和Xyzal，肠易激综合征产品Buscopan，painkiller Doliprane和Pharmaton dietary supplement等品牌-将于2024年第四季度“最早”分开

The business – which has been operating as a standalone business since 2020 and had sales of €1.245 billion in the third quarter – will most likely be set up as a publicly-listed company, headquartered in France, said the pharma group.

该制药集团表示，该业务自2020年以来一直作为独立业务运营，第三季度销售额为12.45亿欧元，最有可能成立总部设在法国的上市公司。

The range of consumer healthcare products it offers will also be “streamlined” ahead of the spin-off. According to the unit’s head, Julie van Ongevalle, becoming a standalone company will provide “increased agility and flexibility to grow our portfolio of brands and further address our customers’ needs across categories.”.

它提供的消费者医疗保健产品范围也将在分拆前“精简”。根据该部门负责人Julie van Ongevalle的说法，成为一家独立公司将提供“增强灵活性和灵活性，以增长我们的品牌组合，并进一步满足客户在各个类别中的需求”。

The separation will enable “greater management focus and resource allocation to the needs of the biopharma business, where value-creating opportunities and longer-term operational levers have been identified to support the accelerated R&D investments,” said Sanofi.

赛诺菲表示，这种分离将使“根据生物制药业务的需要提高管理重点和资源分配，确定创造价值的机会和长期运营杠杆，以支持加速的研发投资”。

Chief executive Paul Hudson said the move will be accompanied by measures to “optimise” Sanofi’s cost structure with the aim of trimming €2.7 billion off its spending that will also be re-invested in R&D and other growth drivers as part of the company’s ‘Play to Win’ strategy.

首席执行官保罗·哈德森（Paul Hudson）表示，这一举措将伴随着“优化”赛诺菲成本结构的措施，目的是削减其27亿欧元的支出，这些支出也将重新投资于研发和其他增长驱动因素，作为公司“打胜利“战略。

That includes a “doubling down on areas where we can make the biggest impact for patients,” he said. Among the projects highlighted as needing additional spending next year are multiple sclerosis candidate frexalimab, vaccines for respiratory syncytial virus and pneumococcal disease, amlitelimab for atopic diabetes and the Johnson & Johnson-partnered extraintestinal pathogenic Escherichia coli (ExPEC) programme, all in phase 3..

他说，这包括“在我们可以对患者产生最大影响的领域加倍”。强调明年需要额外支出的项目包括多发性硬化症候选药物frexalimab，呼吸道合胞病毒和肺炎球菌病疫苗，特应性糖尿病的amlitelimab以及强生合作的肠外致病性大肠杆菌（ExPEC）计划，均在第3阶段。。

Sanofi recorded sales of just under €12 billion in the third quarter, up 3% at constant exchange rates, driven by its specialty care business and particularly immunology blockbuster Dupixent (dupilumab) which grew by a third to €2.8 billion.

赛诺菲在第三季度的销售额仅不到120亿欧元，在其专业护理业务，特别是免疫重磅炸弹Dupixent（dupilumab）的推动下，以恒定汇率上涨3%，增长三分之一至28亿欧元。

The company said new RSV prevention antibody Beyfortus (nirsevimab), once-weekly haemophilia A therapy Altuviio (efanesoctocog alfa) and Tzield (teplizumab) for type 1 diabetes have started strongly since launch, causing it to raise its second-half sales expectations by more than €500 million.

该公司表示，自推出以来，新的RSV预防抗体Beyfortus（nirsevimab），每周一次的血友病A疗法Altuviio（efanesoctocog alfa）和Tzield（teplizumab）治疗1型糖尿病已经开始强劲发展，使其下半年的销售预期提高超过5亿欧元。